A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Read More
TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC
Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.
Read More
EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC
Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
Read More
Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC
The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.
Read More
TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC
Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.
Read More
NSCLC: PD-L1 Expression and Treatment Decision-Making
Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.
Read More
First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer
A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).
Read More
Dr. Sabari on the EVOKE-02 Trial With Sacituzumab Govitecan in NSCLC
November 14th 2023Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.
Read More
Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape
Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Read More
Emerging Targets in Non–Small Cell Lung Cancer
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
Read More
Approach to Treating Patients with NSCLC and RET Fusions
Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.
Read More
Treatment of NTRK Fusions in NSCLC
Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.
Read More
Choosing Between ALK Inhibitors in the Treatment of NSCLC
The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.
Read More
Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Read More
Adagrasib for Patients with KRAS G12C–Mutant NSCLC
Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.
Read More
Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC
Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.
Read More
NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy
Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.
Read More
Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations
Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.
Read More
Treatment Options for Patients with NSCLC with EGFR Mutations
Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.
Read More
Strategies to Improve Biomarker Testing in NSCLC
Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.
Read More
Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC
Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.
Read More
NSCLC: Biomarker Testing Strategies and Turnaround Time
Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.
Read More
Liquid vs Tissue Biopsies in NSCLC
Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.
Read More
Biomarker Testing in Non-Small Cell Lung Cancer
A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.
Read More